值得我国生物医药界警醒。
JHL原来的创始人Racho Jordanov，Rose Lin ...等等被判刑。IP first 。 #年度C点# $赛诺菲-安万特(SNY)$
全球新药浪潮
Drugs insight。穿越周期，洞察全球
- 关注:145
- 粉丝:21747
- 自选:1199
- 组合:0
他的全部讨论
这个册子有引导性，乌帕替尼效果不错，是JAK1$辉瑞(PFE)$ $艾伯维公司(ABBV)$
Folate receptor alpha-targeting antibody-drug conjugate, mirvetuximab soravtansine, was reported in a late breaking abstract with excellent results.$ImmunoGen(IMGN)$
诺和诺德GLP-1在国内不少人Offlabel使用。也不担心副作用。很可怕。
司美格鲁肽注射液近期的新药上市申请正式获药监局/NMPA受理，适应症为：减重适应症，作为低卡路里饮食和增加体力活动的辅助治疗用于初始体重指数≥30kg/m²，或≥27kg/m²且<30kg/m²并且伴有至少一种与超重相关合并症的...
科伦博泰。港股过会。网页链接。ADC，大分子，小分子。$科伦药业(SZ002422)$
AUTL announced the presentation of top-line data from the Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The study showed that 76% of patients treated ach...
卫光生物
6月2日，公司控股股东深圳市光明国资局与中国生物签署合作协议，约定光明国资局与中国生物拟设立合资公司，光明国资局持有合资公司49%股权，中国生物持有合资公司51%股权。合资公司设立后，光明国资局向合资公司无偿划转公司股份7994.7万股，占公司总股本的35.25%。无偿划转后，合资...
$康乃德生物(CNTB)$ S1P1
CNTB announced data at Week 48 from Phase 2 trial (CN002) for icanbelimod (formerly known as CBP-307), a once-daily, orally administered, selective sphingosine 1-phosphate receptor 1 (S1P1) modulator in development for the treatment of ulcerative ...
C4 贝达合作$C4 Therapeutics(CCCC)$ $贝达药业(SZ300558)$
CCCC and Betta Pharmaceuticals Co. Ltd announced an exclusive licensing agreement for the development and commercialization of CFT8919, an orally bioavailable BiDAC degrader designed to be potent and selective again...